Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

a collected to date, and the pending completion of the EDEMA4 confirmatory trial already underway, we believe we will be well positioned to apply for regulatory approval to bring to market this much needed therapy for the HAE patient community. The results, which will be presented next week in more detail, highlight the potential of DX-88 to be a safe and efficacious therapy. Ultimately, we believe DX-88 will greatly improve the quality of life of HAE patients worldwide."

EDEMA3 Trial

EDEMA3, the 72-patient, placebo-controlled, multi-center, Phase 3 trial, was conducted at 34 sites in the United States, Europe, Canada, and Israel. The primary objective of EDEMA3 was to determine the efficacy and safety of the fixed 30 mg subcutaneous (SC) dose of DX-88 for patients suffering from moderate to severe acute HAE attacks. The trial had two phases: a double-blind, placebo-controlled phase and a repeat dosing phase. In the first phase, HAE patients received either a single 30 mg SC dose of DX-88 or placebo. After patients received one treatment in the placebo-controlled portion of the study, they were eligible for the second, open-label phase of the study, where they receive repeat dosing with SC DX-88 for any subsequent attacks.

Webcast Presentation Details

Dyax Corp. will host a webcast presentation on Tuesday, April 17, 2007, which will include a discussion of the EDEMA3 results and the patient reported outcome methodology in more detail. Henry E. Blair, Chairman and CEO of Dyax, will be joined by senior management and clinical trial investigators from the EDEMA3 trial.

Date: Tuesday, April 17, 2007

Time: 12:30 p.m. ET

Online Access: Go to the Investor Relations section of the Dyax website (www.dyax.com) and follow instructions for accessing the live webcast. Participants may register in advance.

Telephone Access: Domestic callers, dial 1-888-396-2384

International callers, dial 617-847-8711

Passcode
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation

Post Your Comments:
(Date:11/29/2009)... , CHICAGO, Nov. 29 Research...MRI) to study brain activation have found that men...ative stimuli, according to a study presented toda...y of North America (RSNA). ,, "Men may direct m...uli and tend to process them in terms of implicati...
(Date:11/27/2009)... , Another option to prevent illnesses..., SILVER SPRING, Md., Nov. 27 /PRNewswire-USNewswi... approved Agriflu for people ages 18 years and old...btypes A and B. ,, (Logo: http://www.newscom..., manufactured by Novartis Vaccines and Diagnostic...
(Date:11/27/2009)... , BLOOMINGTON, Minn, Nov. 27 ... medical image management software, data migration...he United States Patent and Trademark Office has a...cation Format within a Computer Network." Acuo Tec... portfolio of intellectual property. In general, t...
Breaking Medicine Technology:New Study Finds Men and Women May Respond Differently to Danger 2New Study Finds Men and Women May Respond Differently to Danger 3FDA Approves Agriflu Seasonal Influenza Vaccine 2Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Americans United for Life Action Endorses a Vote for the Stupak Ellsworth Pitts Kaptur Dahlkemper Lipinski Smith Amendment and Sends Score Letter to H 60894 1Americans United for Life Action Endorses a Vote for the Stupak Ellsworth Pitts Kaptur Dahlkemper Lipinski Smith Amendment and Sends Score Letter to H 60894 2Binge Drinking Puts the Brain and Life Itself at Risk 60891 1Binge Drinking Puts the Brain and Life Itself at Risk 60891 2Binge Drinking Puts the Brain and Life Itself at Risk 60891 3Cardiome to Release Third Quarter Results 60886 1Cardiome to Release Third Quarter Results 60886 2Cardiome to Release Third Quarter Results 60886 3
...ration aimed at enabling vaccine production facili...ditional egg-based facility., * Once established,... of, pandemic flu vaccine to commence within 12 w...England and ROCKVILLE, Md., Dec. 10, GE Healthcare... and Novavax Inc. (Nasdaq: NVAX ), today announce...
...ives include restructuring and pipeline prioritiza...c.,(Nasdaq: RDYN ) today announced an operational...rategic priorities. These priorities include,ident...otic, faropenem,medoxomil (faropenem), advancing a...exploring additional corporate development opportu...
Other Medicine Technology:GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution 2GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution 3GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution 4Replidyne Provides Strategic Update 2Replidyne Provides Strategic Update 3Replidyne Provides Strategic Update 4Replidyne Provides Strategic Update 5Replidyne Provides Strategic Update 6
(Date:11/26/2009)...ov. 27 With cold and flu season up...d practices to control the spread of infections an...t only to keep ourselves healthy, but to avoid tra...rty, RN, MS, CIC (certified in infection-control),...tional health at Hospital for Special Surgery (HSS...
(Date:11/26/2009)... the number of Americans living with diabetes will...09 to 44.1 million in 2034. Over the same period, ...om $113 billion to $336 billion, even with no incr...ed at the University of Chicago report in the Dece...hose with diabetes covered by Medicare will rise f...
(Date:11/26/2009)...or too heavy can lead to strains or worse , ...may be nothing wrong with stuffing your turkey ful...me thing with your suitcase as you pack for holida... in 2008 in U.S. hospital emergency rooms, doctors...r luggage-related injuries, such as muscle strains...
(Date:11/26/2009)... No more letters from the North Pole, Textsanta....sages from Santa , North ...tional efficiencies at the North Pole Santa Claus ... all over the globe informed of his Christmas prog... research department have identified a large and g...
(Date:11/26/2009)... Research Triangle Dental (RTDental), a leading ...oday announced the expansion of its services to in...r. Doug Macmillan. , D...leased to announce that Dr. Doug Macmillan, an exp...n additional advanced training seminar. RTDental&...
Breaking Medicine News(10 mins):Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
... If Pfizer and Wyeth merge to create a...bad deal? Fintan Walton, PhD, CEO of PharmaVenture... both companies. , Oxford...CEO of PharmaVentures, says, ‘This is potent...
...nce the introduction of the life-saving clot-busti...een accumulating that tPA (tissue-type plasminogen...n affected by stroke. Although it remains the only...edicine are testing strategies for blocking LRP1, ...
...Full Year 2008 Revenue of Approximately $250 Milli...of $345 Million to $350 Million , , SAN DIEGO, Ja... device company focused on developing products for...2008 and provided financial guidance for the full ...
...C., Jan. 23 As the health insurance market increa...ld of South Carolina is seeking to serve customers...st retail outlet, which has its grand opening toda...lueStore(SM) will open officially with a ribbon c...
.... 23 President Barack Obama is the first new Presi... While the plan reflects strong emphasis on oncolo...n, and the wide range of avoidable causes of cance...l trials; the Centers for Disease Control and Pre...
...d DEPTFORD, N.J., Jan. 23 In an effort to keep pa...and Licensed Practical Nurses are set to participa...ptford and Innova Hammonton scheduled to begin at ...ave been working without a contract since last Apr...
Other Medicine News:Health News:Pfizer - Wyeth: Good Deal – Bad Deal? 2Health News:Blocking toxic effects could make clot-buster safer 2Health News:NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results 2Health News:NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results 3Health News:NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results 4Health News:S.C. BlueCross Hosts Grand Opening of Its First Health Insurance Retail Store 2Health News:The Obama Cancer Plan Should Prioritize Prevention, Says Cancer Prevention Coalition 2Health News:The Obama Cancer Plan Should Prioritize Prevention, Says Cancer Prevention Coalition 3Health News:The Obama Cancer Plan Should Prioritize Prevention, Says Cancer Prevention Coalition 4Health News:The Obama Cancer Plan Should Prioritize Prevention, Says Cancer Prevention Coalition 5
Rad-9™
Avant® 9700
"Immersol"
Immersion - Glycerin
Medicine Products: